Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766888 | PMC |
| http://dx.doi.org/10.3201/eid2203.151158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Virus-Like Particles Carrying HIV-1 Env with a Modulated Glycan Composition].
Mol Biol (Mosk)
December 2024
Gamaleya Federal Research Center of Epidemiology and Microbiology, Moscow, 123098 Russia.
Previously obtained highly immunogenic Env-VLPs ensure overcoming the natural resistance of HIV-1 surface proteins associated with their low level of incorporation and inaccessibility of conserved epitopes to induce neutralizing antibodies. We also adopted this technology to modify Env trimers of the ZM53(T/F) strain to produce Env-VLPs by recombinant vaccinia viruses (rVVs). For VLP production, rVVs expressing Env, Gag-Pol (HIV-1/SIV), and the cowpox virus hr gene, which overcomes the restriction of vaccinia virus replication in CHO cells, were used.
View Article and Find Full Text PDFMolecular analysis of the 2022 mpox outbreak and antiviral activity of dihydroorotate dehydrogenase inhibitors against orthopoxviruses.
Antiviral Res
January 2025
Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany. Electronic address:
Article Synopsis
- Monkeypox virus (MPXV) caused a significant outbreak in 2022, with over 90,000 cases and 181 fatalities, exhibiting signs of evolution and adaptation to hosts.
- Research revealed that different MPXV isolates from the Franconia region have mutations affecting their replication capabilities, particularly a variant with a mutation (D616L) that shows faster viral replication.
- The study also found that dihydroorotate dehydrogenase (DHODH) inhibitors are effective against MPXV and related viruses, offering promising low-toxicity options for future antiviral drug development.
An Attenuated and Highly Immunogenic Variant of the Vaccinia Virus.
Acta Naturae
January 2024
State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk region, 630559 Russian Federation.
Article Synopsis
- - The vaccinia virus has been historically used as a smallpox vaccine, but due to its reactogenicity, WHO recommended discontinuation after smallpox was eradicated, leading to a rise in orthopoxvirus infections, notably the 2022 monkeypox epidemic.
- - Researchers developed modified VACV strains, LAD and LADA, with specific genetic alterations to reduce reactogenicity while enhancing the immune response compared to the original L strain.
- - Both LAD and LADA strains demonstrated superior cellular immune responses and higher levels of VACV-specific IgG in vaccinated mice, indicating their potential as safer and more effective vaccines against orthopoxvirus infections.
Poxviridae Pneumonia.
Adv Exp Med Biol
May 2024
Pulmonology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Article Synopsis
- The Poxviridae family includes viruses that mainly cause skin lesions in humans but can complicate into pneumonia, especially in immunocompromised individuals.
- The variola virus, responsible for smallpox, was associated with severe pneumonia outbreaks historically and remains a concern for biological threats.
- Treatments focus on supportive care and FDA-approved antiviral drugs, with two vaccines available to prevent smallpox and protect against related infections like MPXV.
Article Synopsis
- * The assay demonstrated high analytical sensitivity at 50 copies/mL for both clades I and II of MPXV, with clinical sensitivity and specificity rates of 99.21% and 96.64%, respectively.
- * This assay streamlines laboratory processes by integrating nucleic acid extraction and PCR analysis and is crucial for distinguishing between MPXV clades, which is vital for safety in handling potentially regulated samples.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!